Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Veru (NASDAQ: VERU) reported fiscal 2026 third quarter results and clinical progress for enobosarm. For the quarter ended June 30, 2026, research and development expenses were $4.4 million and general and administrative expenses were $3.4 million, leading to an operating loss of $7.7 million and a net loss of $7.0 million, or $0.30 per share. Cash, cash equivalents and restricted cash were $23.9 million versus $15.8 million at September 30, 2025.
According to Veru, the Phase 2b PLATEAU obesity trial of enobosarm plus semaglutide is fully enrolled with 239 patients, exceeding the 200-patient target. Interim DXA-based results are expected in Q1 2027 and final topline data in Q4 2027. The company highlighted prior positive Phase 2b QUALITY data and received a USPTO Notice of Allowance for a key U.S. patent covering enobosarm–semaglutide regimens, expected to provide protection until at least October 2044.
Veru (NASDAQ: VERU) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a key U.S. patent application covering enobosarm, a selective androgen receptor modulator, in combination with the weight loss drug semaglutide and as monotherapy before and after semaglutide treatment.
The allowed claims cover preserving lean and muscle mass, enhancing fat loss, maintaining physical function and bone, improving insulin resistance and HbA1c, and reducing weight and fat regain after stopping semaglutide. When issued, the patent will run to at least October 3, 2044 and adds to Veru’s existing enobosarm composition-of-matter and formulation IP, including applications that could protect certain formulations until at least May 2046. Veru is also running the fully enrolled Phase 2b PLATEAU trial and has reported positive results from the Phase 2b QUALITY study of enobosarm plus semaglutide in older patients with obesity.
Veru (NASDAQ: VERU) will host a conference call and audio webcast on Monday, August 10, 2026 at 8:00 a.m. ET to discuss its fiscal 2026 third quarter financial results and provide a business update. Investors can access the live webcast from the Home and Investors pages of Veru’s website, or join by telephone using domestic and international dial-in numbers. Replay options will be available via webcast for about three months and by telephone for one week.
Veru also highlights its obesity program, including the fully enrolled Phase 2b PLATEAU trial of enobosarm with semaglutide and the completed Phase 2b QUALITY study, which showed positive effects on lean mass, physical function, fat loss, and weight maintenance.
Veru (NASDAQ: VERU) announced that Chairman, President and CEO Mitchell Steiner, M.D., will participate in a fireside chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 12, 2026, from 2:00–2:25 p.m. EDT. A live and archived webcast will be available in the Investors section of Veru’s website.
Veru highlighted its obesity program evaluating enobosarm with GLP‑1 receptor agonists. The Phase 2b PLATEAU study in approximately 200 older patients with obesity is fully enrolled, with interim DXA results expected in Q1 2027 and topline data in Q4 2027. Veru also noted positive results from the completed Phase 2b QUALITY and maintenance extension study, which evaluated enobosarm plus semaglutide and then enobosarm monotherapy for weight management outcomes in older patients.
Veru (NASDAQ: VERU) reported full enrollment, exceeding its target of 200 patients, in the Phase 2b PLATEAU trial evaluating oral enobosarm 3 mg versus placebo in older patients (≥65 years) with obesity (BMI ≥35) who are starting semaglutide for weight reduction. The double-blind, placebo-controlled study will assess effects on total body weight, fat mass, lean mass, physical function, bone mineral density, and safety over 68 weeks.
According to Veru, interim DXA-based results on lean and fat mass after 32 weeks are expected in calendar Q1 2027, with final topline data anticipated in Q4 2027. The company highlights prior positive Phase 2b QUALITY data, where enobosarm plus semaglutide preserved lean mass and physical function, increased fat loss over 16 weeks, and enobosarm monotherapy helped prevent weight regain after GLP-1 RA discontinuation.
Veru (NASDAQ: VERU) will present at the 2026 4th Annual Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day in Boston on July 14-16, 2026.
Company leaders will discuss geriatric sarcopenic obesity therapies and evolving obesity drug development endpoints.
Veru (NASDAQ:VERU) reported fiscal 2026 Q2 results and progress in its enobosarm obesity program. Research and development expenses fell to $3.1 million from $3.9 million, and general and administrative expenses to $4.1 million from $5.2 million.
Operating loss from continuing operations decreased to $7.2 million from $8.1 million, and net loss to $2.7 million, or $0.12 per share, from $7.9 million, or $0.54 per share. Cash rose to $27.6 million from $15.8 million. The Phase 2b PLATEAU trial in older obese patients on semaglutide is actively enrolling, with interim DXA-based data expected in early 2027 and topline data in late 2027, building on positive Phase 2b QUALITY results.
Veru (NASDAQ: VERU) will report fiscal 2026 second quarter financial results and provide a business update on Wednesday, May 13, 2026 at 8:00 a.m. ET. The company will host a conference call and audio webcast; replay options will be available online and by telephonic replay.
Access the live webcast and archived replay via the Home or Investors page at verupharma.com. Telephone dial-in numbers and replay passcode are provided for domestic and international callers.
Veru (NASDAQ: VERU) enrolled the first patient in the Phase 2b PLATEAU trial testing oral enobosarm 3mg plus injectable semaglutide in ~200 older patients (age ≥65, BMI ≥35) with obesity to preserve lean mass, physical function and bone while augmenting fat and weight loss.
An interim DXA analysis is expected in Q1 2027 (34 weeks) and final topline data in Q4 2027 (primary endpoint: percent change in total body weight at 68 weeks).
Veru (NASDAQ: VERU) announced that Mitchell Steiner, M.D., Chairman, President and CEO, will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 from 3:20 pm to 3:50 pm ET.
A live webcast will be accessible via the company website and an archived webcast will be posted after the event.